- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Kira Pharmaceuticals LLC
Headquarters: Cambridge, MA, United States
Website: https://www.kirapharma.com/
Year Founded: 2017
Status: Private
BioCentury | Nov 13, 2024
Management Tracks
Rubedo names Frederick Beddingfield CEO
Plus: Kian Teik Beh succeeds Frederick Chew at A*STAR, and updates from Climb Bio, DiogenX, Arch, SR One and Koneksa
BioCentury | May 11, 2023
Management Tracks
McKinsey vet Dewhurst joins Lightrock
Plus: Wugen appoints Alles as chair and updates from Cerevel, Ribbon, Immodulon and more
BioCentury | Apr 28, 2023
Management Tracks
Ball succeeds Maderis as CEO of Antiva
Plus: Valente joins Xencor and updates from Sutro, Gameto and more
BioCentury | Feb 8, 2023
Data Byte
Competition heats up in PNH with new Roche data
A dozen complement inhibitors behind Roche’s crovalimab also hope to challenge established therapies
BioCentury | Nov 17, 2021
Management Tracks
Rhee steps down as CEO of Korea’s SCM
Recludix, Ankyra unveil venture rounds and new execs; plus ImmunoGen, Talis, Kira, Sonoma, Spruce, Ankyra and more
BioCentury | Jan 8, 2021
Deals
Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more
Cullinan upsizes IPO for $250M raise Cullinan Management Inc. (NASDAQ:CGEM) raised $249.9 million in an IPO via the sale of 11.9 million shares at $21. The company had planned to sell 10 million
BioCentury | Nov 13, 2020
Emerging Company Profile
Kira: overcoming the complexities of complement
Emerging Company Profile: Kira debuts with Beddingfield as CEO, three programs slated to enter clinic over 18 months
Items per page:
1 - 7 of 7